AVROPRIN

This brand name is authorized in Nigeria.

Active ingredients

The drug AVROPRIN contains one active pharmaceutical ingredient (API):

1
UNII R16CO5Y76E - ASPIRIN
 

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs.

 
Read more about Acetylsalicylic acid

Packages

This drug has been approved in Nigeria as follows:

Identifier Form Presentation Description Approval
A11-0681 Tablet AVROPRIN 300MG TABLET TAB 300 mg x1000, x500 12 RNW-PP-289168 AVROPRIN 300MG TABLET ASPIRIN (ACETYL SALICYLIC ACID) ASPIRIN 300MG, POVIDONE K-30, TALC, STEARIC ACID, AVICEL PH 101, MAIZE STARCH, ISOPROPYL ALCOHOL A11-0681 Drugs Nigerian Products x1000,x500 OTC 11/15/2022 AVRO PHARMA LIMITED, DAID HOUSE, PLOT 2,BLOCK J, LIMCA WAY, ISOLO INDUSTRIAL ESTATE, OSHODI APAPA, EXPRESSWAY, ISOLO, LAGOS, NIGERIA 17410411 lewachionline@yahoo.com SKG-PHARMA LIMITED, 7/9 SAPARA STREET, OFF OBA AKRAN AVENUE, IKEJA, LAGOS., Nigeria 31/10/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N02BA01 Acetylsalicylic acid N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BA Salicylic acid and derivatives
Discover more medicines within N02BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
NG Registered Drug Product Database A11-0681

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.